Merck KGaA Moderates New Drug Sales Ambitions For 2022
Raises Financial Guidance For 2021
Merck KGaA has narrowed its 2022 sales forecasts for its newly launched pharmaceuticals because of the COVID-19 pandemic, but still expects strong growth from these products and from products and services in its process solutions and electronic businesses.
